

Adult Thoracic - Heart/Lung Transplant Recipient Registration Worksheet

FORM APPROVED: O.M.B. NO. 0915-0157 Expiration Date: 12/31/2011

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI® application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI® application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Name:	DOB:
SSN:	Gender:
HIC:	Tx Date:
State of Permanent Residence: *	
Permanent Zip: *	
Recipient Center:	
Physician Name: **	
Physician NPI#: *	
Surgeon Name: *	
Surgeon NPI#: *	
,	
UNOS Donor ID #:	
Donor Type:	
Primary Diagnosis: *	
Specify:	
Date: Last Seen, Retransplanted or Death ★	
	LIVING
Patient Status: *	0
	DEAD
	RETRANSPLANTED

Primary Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Contributory Cause of Death: Specify:	
Transplant Hospitalization:	
Date of Admission to Tx Center: ★	
Date of Discharge from Tx Center:	
Was patient hospitalized during the last 90 days prior to the transplant admission:	C YES C NO C UNK
	IN INTENSIVE CARE UNIT
Medical Condition: ★	C HOSPITALIZED NOT IN ICU
	NOT HOSPITALIZED
Patient on Life Support: *	C YES NO
	Extra Corporeal Membrane Oxygenation
	Intra Aortic Balloon Pump
	Prostacyclin Infusion
	Prostacyclin Inhalation
	Inhaled NO
	Ventilator
	Other Mechanism

Specify:	
Patient on Ventricular Assist Device ★	NONE LVAD RVAD TAH LVAD+RVAD
Life Support: VAD Brand1	
Specify:	
Life Support: VAD Brand2	
Specify:	
Functional Status: *	
Physical Capacity:	No Limitations Limited Mobility Wheelchair bound or more limited Not Applicable (< 1 year old or hospitalized) Unknown
Working for income: *	C YES C NO C UNK
If No, Not Working Due To:	
If Yes:	Working Full Time Working Part Time due to Demands of Treatment Working Part Time due to Disability Working Part Time due to Insurance Conflict

Е

	Working Part Time due to Inability to Find Full Time Work
	Working Part Time due to Patient Choice
	Working Part Time Reason Unknown
	Working, Part Time vs. Full Time Unknown
	Within One Grade Level of Peers
	Delayed Grade Level
Academic Progress:	Special Education
	Not Applicable < 5 years old/ High School graduate or GED
	Status Unknown
	C Full academic load
	0
Academic Activity Level:	Reduced academic load
Academic Activity Level.	Unable to participate in academics due to disease or condition
	Not Applicable < 5 years old/ High School graduate or GED
	Status Unknown
Source of Payment:	
Primary: *	
Specify:	
Secondary:	
-	
Height: *	ft. in. cm ST=
Weight: *	lbs kg ST=
BMI:	kg/m ²

Previous Transplants:

	Previous	Transpl	lant O	rgan
--	----------	---------	--------	------

Previous Transplant Date

Previous Transplant Graft Fail Date

The three most recent transplants are listed here. Please contact the UNet Help Desk to confirm more than three previous transplants by calling 800-978-4334 or by emailing unethelpdesk@unos.org.

Viral Detection:		
VIII. Botostoni	_	
	0	Positive
HIV Serostatus: ★	0	Negative
	0	Not Done
	0	UNK/Cannot Disclose
	0	Positive
01111 0 W	0	Negative
CMV IgG: ★	0	Not Done
	0	UNK/Cannot Disclose
	0	Positive
ate.	0	Negative
CMV IgM: *	0	Not Done
	0	UNK/Cannot Disclose
HBV Core Antibody: ★	0	Positive
	0	
	0	Negative
	0	Not Done
		UNK/Cannot Disclose
HBV Surface Antigen: ★	0	Positive
	0	Negative
	0	Not Done
	0	UNK/Cannot Disclose
HCV Serostatus: ★	0	Positive

	0	Negative				
	0	Not Done				
	0	UNK/Cannot Disclose				
	0	Positive				
EBV Serostatus: ★	0	Negative				
EBV Serostatus:	0	Not Done				
	0	UNK/Cannot Disclose				
Most Recent Hemodynamics:				Inotrop	es/Vasodil	ators:
PA (sys)mm/Hg: *			ST=	_	YES C	NO
PA(dia) mm/Hg: *			ST=	0	YES C	NO
PA(mean) mm/Hg: **			ST=	0	YES C	NO
PCW(mean) mm/Hg: ★			ST=	0	YES C	NO
CO L/min: *			ST=	0	YES C	NO
Most Recent Serum Creatinine: *		mg/dl	ST=			
Most Recent Total Bilirubin: ★		mg/dl	ST=			
Oxygen Requirement at Rest:		L/min	ST=			
Chronic Steroid Use: ★	0	YES NO UNK				
Pulmonary Status (Give most recent value):						
FVC: *		%predicted:	ST=			
FeV1: *		%predicted:	ST=			
pCO2: *		mm/Hg:	ST=			

Events occurring between listing and transplant:

Transfusions: *	0	YES O	NO C	UNK
Infection Requiring IV Therapy within 2 wks prior to Tx: *	0	YES O	NO O	UNK
Cerebrovascular Event:	0	YES C	NO C	UNK
Dialysis: *	0	YES C	NO C	UNK
Implantable Defibrillator:	0	YES C	NO O	UNK
Prior Cardiac Surgery (non-transplant): ★	0	YES O	NO C	UNK
If yes, check all that apply:		Congeni	tricular Rer	
Specify:				
Prior Lung Surgery (non-transplant): ★	0	YES C	NO C	UNK
If yes, check all that apply:		Pneumoi Lobector Pneumoi Left Thor	thorax Dec my nectomy racotomy oracotomy	
Specify:				

Episode of Ventilatory Support: *	0	YES NO UNK
If yes, indicate most recent timeframe:	0 0 0	At time of transplant Within 3 months of transplant
Tracheostomy: *	0	>3 months prior to transplant YES NO UNK
	0	NO PREVIOUS PREGNANCY
	0	1 PREVIOUS PREGNANCY
	0	2 PREVIOUS PREGNANCIES
	0	3 PREVIOUS PREGNANCIES
Previous Pregnancies:	0	4 PREVIOUS PREGNANCIES
	0	5 PREVIOUS PREGNANCIES
	0	MORE THAN 5 PREVIOUS PREGNANCIES
	0	NOT APPLICABLE: < 10 years old
	0	UNKNOWN
Malignancies between listing and transplant: *	0	YES O NO UNK
This question is NOT applicable for patients receiving living	donor tra	nsplants who were never on the waiting list.
		Skin Melanoma
		Skin Non-Melanoma
		CNS Tumor
If yes, specify type:		Genitourinary
		Breast
		Thyroid
		Tongue/Throat/Larynx

Specific		Lung Leukemia/Lymphoma Liver Other, specify
Specify: Multiple Organ Recipient Were extra vessels used in the transplant procedure:		
Vessel Donor ID: Procedure Type:	0 0	Heart Heart Lung
Was this a retransplant due to failure of a previous thoracic graft:	0	YES NO
Total Organ Ischemia Time (include cold, warm and anas Heart, Heart-Lung:	tomotic	c time):
Incidental Tumor found at time of Transplant: If yes, specify tumor type:	0 0 0 0 0 0 0	Carcinoma
Specify:		

Graft Status: ★	C Functioning Failed
	Functioning Failed sult of some other factor unrelated to graft failure, select Functioning.
Date of Graft Failure:	
Primary Cause of Graft Failure:	Primary Non-Function Acute Rejection Chronic Rejection/Atherosclerosis
Specify:	Other, Specify
Events Prior to Discharge:	
Any Drug Treated Infection:	C YES C NO C UNK
Stroke: *	C YES C NO C UNK
Dialysis: *	C YES C NO C UNK
Cardiac Re-Operation:	C YES C NO C UNK
Other Surgical Procedures:	C YES C NO C UNK
Time on inotropes other than Isoproterenol (Isuprel):	days ST=
Ventilator Support: 米	 No Ventilator support for <= 48 hours Ventilator support for >48 hours but < 5 days Ventilator support >= 5 days Ventilator support, duration unknown Unknown Status

Reintubated: *	O YES O NO O UNK
Permanent Pacemaker: *	C YES C NO UNK
Chest drain >2 weeks:	C YES C NO UNK
Airway Dehiscence: *	C YES C NO C UNK
	Yes, at least one episode treated with anti-rejection agent
Did patient have any acute rejection episodes between transplant and discharge: ★	Yes, none treated with additional anti-rejection agent
, <u>.</u> .	C No
	© Biopsy not done
Was biopsy done to confirm acute rejection:	Yes, rejection confirmed
	Yes, rejection not confirmed
Biological or Anti-viral Therapy:	C YES NO Unknown/Cannot disclose
	Acyclovir (Zovirax)
	Cytogam (CMV)
	Gamimune
	Gammagard
If Yes, check all that apply:	Ganciclovir (Cytovene)
	Valgancyclovir (Valcyte)
	HBIG (Hepatitis B Immune Globulin)
	П
	Flu Vaccine (Influenza Virus)
	Lamivudine (Epivir) (for treatment of Hepatitis B)
	Other, Specify

	Valacyclovir (Valtrex)
Specify:	
Specify:	
Other therapies:	C YES C NO
	Photopheresis
If Yes, check all that apply:	Plasmapheresis
	Total Lymphoid Irradiation (TLI)
Are any medications given currently for maintenance or anti-rejection: *	C YES C NO
Did the patient participate in any clinical research protocol for immunosuppressive medications:	C YES C NO
If Yes, Specify:	
View Immunosuppressive Medications	
Definitions Of Immunosuppressive Medications	
	Previous Maintenance (Prev Maint), Current Maintenance (Curr Maint) or Anti- d for the recipient during this follow-up period, and for what reason. If a medication was
clinic visit to the current clinic visit, for varying periods of time	pressive medications given during the report period, which covers the period from the last which may be either long-term or intermediate term with a tapering of the dosage until the ntenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, nosuppressive medications given to treat rejection episodes.
periods of time which may be either long-term or intermediate	ressive medications given at the current clinic visit to begin in the next report for varying term with a tapering of the dosage until the drug is either eliminated or replaced by yclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does t rejection episodes.
since the last clinic visit (example: Methylprednisolone, Atgam Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to immunosuppression, but should be listed under maintenance	suppressive medications given for the purpose of treating an acute rejection episode , OKT3, or Thymoglobulin). When switching maintenance drugs (example: from Azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression. nedications since the last clinic visit, not just at the time of the current clinic visit.
	being administered (e.g., new monoclonal antibodies), select Previous Maint, or Current ld, and enter the full name of the medication in the space provided. Do not list non-

that were prescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank.

Induction (Ind) immunosuppression includes all medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection. Though the drugs may be continued after discharge for the first 30 days after transplant, it will not be used long-term for immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (example: Methylprednisolone, Atgam, Thymoglobulin, OKT3, Simulect, or Zenapax). Some of these drugs might be used for another finite period for rejection therapy and would be recorded as rejection therapy if used for this reason. For each induction medication indicated, write the total number of days the drug was actually administered in the space provided. For example, if Simulect or Zenapax was given in 2 doses a week apart, then the total number of days would be 2, even if the second dose was given after the patient was discharged.

Maintenance (Maint) includes all immunosuppressive medications given before, during or after transplant for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes, or for induction.

Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode during the initial post-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. <u>Do not list non-immunosuppressive medications.</u>

Steroids	Ind.	Days	ST	Maint	AR	
(Prednisone, Methylprednisolone, Solumedrol, Medrol, Decadron)			_			
Atgam (ATG)			_			
OKT3 (Orthoclone, Muromonab)			_			
Thymoglobulin			_			
Simulect - Basiliximab			_			
Zenapax - Daclizumab			_			
Azathioprine (AZA, Imuran)			_			
EON (Generic Cyclosporine)			_			
Gengraf (Abbott Cyclosporine)			_		П	
Other generic Cyclosporine, specify brand:			_			
Neoral (CyA-NOF)			_		П	
Sandimmune (Cyclosporine A)			_			
CellCept (Mycophenolate Mofetil; MMF)						

Generic MMF (Generic CellCept)				
Prograf (Tacrolimus, FK506)				
Generic Tacrolimus (Generic Prograf)				
Advagraf (Tacrolimus Extended or Modified Release)				
Nulojix (Belatacept)				
Sirolimus (RAPA, Rapamycin, Rapamune)				
Myfortic (Mycophenolate Sodium)				
Compath Alamturumah (arti CD52)	Ind. Days	ST	Maint	AR
Campath - Alemtuzumab (anti-CD52)		ST		
Campath - Alemtuzumab (anti-CD52) Cyclophosphamide (Cytoxan)	_	ST	1 —	AR
		ST		
Cyclophosphamide (Cytoxan)		ST		
Cyclophosphamide (Cytoxan) Leflunomide (LFL, Arava) Methotrexate (Folex, PFS, Mexate-AQ,		ST		
Cyclophosphamide (Cytoxan) Leflunomide (LFL, Arava) Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)		ST		
Cyclophosphamide (Cytoxan) Leflunomide (LFL, Arava) Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex) Other Immunosuppressive Medication, Specify		ST		
Cyclophosphamide (Cytoxan) Leflunomide (LFL, Arava) Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex) Other Immunosuppressive Medication, Specify		ST		
Cyclophosphamide (Cytoxan) Leflunomide (LFL, Arava) Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex) Other Immunosuppressive Medication, Specify				